Alfred Lordi

Alfred Lordi is a seasoned professional in the pharmaceutical and biotechnology sectors, currently serving as the Director of DMPK at Quanta Therapeutics since December 2023, focusing on the development of allosteric inhibitors for RAS-driven cancers. Previously, Alfred held the role of Director of Preclinical Services and Director of Sample/Compound Receiving at WuXi AppTec from May 2015 to November 2023, overseeing various laboratory operations. Alfred’s extensive experience includes roles as Associate Director of Discovery/Preclinical DMPK at QPS, LLC and Senior Group Leader at QPS, LLC from 2002 to 2015. Early career positions include Associate Scientist at Schering-Plough Research Institute and Certified Technician at Bio/dynamics, Inc. Alfred holds a Master of Science in Biology from Seton Hall University and a Bachelor of Science in Animal Sciences from Rutgers University.